Formulation development and primary degradation pathways for recombinant human nerve growth factor

被引:24
作者
Eng, M
Ling, V
Briggs, JA
Souza, K
CanovaDavis, E
Powell, MF
DeYoung, LR
机构
[1] GENENTECH INC,DEPT MED & ANALYT CHEM,S SAN FRANCISCO,CA 94080
[2] GENENTECH INC,DEPT PHARMACEUT RES & DEV,S SAN FRANCISCO,CA 94080
关键词
D O I
10.1021/ac9704016
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
The chemical and physical stabilities of recombinant human nerve growth factor (NGF) in aqueous solution were investigated between 5 and 37 degrees C and at pH 4.2-5.8. NGF chemical stability decreased with a decrease in pH due to Asp(60)-Pro(61) cleavage, with the stability being greater in acetate buffer than in succinate buffer at each pH investigated. Aggregation was a significant degradation pathway at 37 degrees C, with the aggregation rate being greatest in succinate buffer at pH 5.8. Quantitation of NGF degradation by cation-exchange chromatography was complicated by the rearrangement of the NGF monomer variants into various mixed dimers over time. Treatment with dilute acid brought the dimer distribution rapidly to equilibrium, allowing NGF degradation to be accurately quantitated. An acetate-buffered formulation at pH 5.5 was investigated in more detail, go assist in degradation product identification, NGF degradation was accelerated with base, hydrogen peroxide, and temperature, These degradation products were shown to coelute on RP-HPLC with the variants found when the protein was stored at -70, 5, and 25 degrees C, By electrospray mass spectrometry, peptide maps, and LC/MS, these degradation products were shown to be monooxidized (Met(37)) and dioxidized (Met(37) and Met(92)) NGF, with Met(37) being more labile, deamidated NGF (Asn(45)), and NGF with Asp(93) isomerized to beta-Asp(93). NGF can be stored in pH 5.5 acetate buffer at 5 degrees C for 1.5 years with less than 10% conversion to these degradation products, with Asp(93) isomerization being the primary degradation pathway.
引用
收藏
页码:4184 / 4190
页数:7
相关论文
共 23 条
  • [1] NERVE GROWTH-FACTOR PREVENTS EXPERIMENTAL CISPLATIN NEUROPATHY
    APFEL, SC
    AREZZO, JC
    LIPSON, L
    KESSLER, JA
    [J]. ANNALS OF NEUROLOGY, 1992, 31 (01) : 76 - 80
  • [2] APFEL SC, 1991, NEUROLOGY, V28, P87
  • [3] BODANSZKY M, 1978, INT J PEPT PROT RES, V12, P69
  • [4] BOTHWELL MA, 1977, J BIOL CHEM, V252, P8532
  • [5] THE BIOCHEMISTRY OF METHIONINE SULFOXIDE RESIDUES IN PROTEINS
    BROT, N
    WEISSBACH, H
    [J]. TRENDS IN BIOCHEMICAL SCIENCES, 1982, 7 (04) : 137 - 139
  • [6] CANOVADAVIS E, 1993, PEPTIDES CHEM STRUCT, P230
  • [7] CLELAND JL, 1993, CRIT REV THER DRUG, V10, P307
  • [8] DEYOUNG LR, 1994, BIOPHYS J, V66, pA401
  • [9] GEIGER T, 1987, J BIOL CHEM, V262, P785
  • [10] GREENE LA, 1977, BRAIN RES, V133, P350, DOI 10.1016/0006-8993(77)90770-3